These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26473092)

  • 1. Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea.
    Lee M
    Osong Public Health Res Perspect; 2015 Aug; 6(4):249-55. PubMed ID: 26473092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Determinants of Research and Development Investment in the Pharmaceutical Industry: Focus on Financial Structures.
    Lee M; Choi M
    Osong Public Health Res Perspect; 2015 Oct; 6(5):302-9. PubMed ID: 26730355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea.
    Lee M; Choi M
    Osong Public Health Res Perspect; 2015 Aug; 6(4):241-8. PubMed ID: 26473091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equity Structure, Strategic Investment Psychology, and Performance in China's Green Economy Context.
    Guo LX; Lin KL; Zhang LT; Liu CF
    Front Psychol; 2021; 12():707582. PubMed ID: 34512465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Institutional investors and cost of capital: The moderating effect of ownership structure.
    Huo X; Lin H; Meng Y; Woods P
    PLoS One; 2021; 16(4):e0249963. PubMed ID: 33831116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can fund shareholding inhibit insufficient R&D input?--Empirical evidence from Chinese listed companies.
    Li X; Liu G
    PLoS One; 2021; 16(3):e0248674. PubMed ID: 33765071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualified foreign institutional investors and corporate innovation: From the perspective of corporate governance.
    Wang X; Wang W; Shi XY
    Front Psychol; 2022; 13():1005409. PubMed ID: 36467163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of companies disclosing ESG reports in multiple languages on the enthusiasm of foreign investors for holding shares.
    Bao R; Wei L
    PLoS One; 2024; 19(3):e0299643. PubMed ID: 38452011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research on the impact of technology mergers and acquisitions on corporate performance: an empirical analysis based on China's pharmaceutical industry.
    Yang J; Li J; Wang S; Chen Y
    Front Public Health; 2024; 12():1419305. PubMed ID: 39185128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Cross-Shareholding Conducive to Corporate Sustainability? Evidence From the Environmental Investment of Chinese Listed Firms.
    Tian J; Cao W; Ji X
    Front Psychol; 2021; 12():789811. PubMed ID: 34803864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health.
    Roller S
    Global Health; 2019 Nov; 15(1):55. PubMed ID: 31690328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E; Kim TH; Jeung MJ; Lee EK
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does environmental regulation truly enhance corporate green environmental investment? Evidence from the supervision of independent directors in listed companies.
    Wang C; Wang F; Jiang P
    Front Psychol; 2024; 15():1430137. PubMed ID: 39315041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial influence on global risks of zoonotic emerging and re-emerging diseases: an integrative analysis.
    Galaz V; Rocha J; Sánchez-García PA; Dauriach A; Roukny T; S Gaard J Rgensen P
    Lancet Planet Health; 2023 Dec; 7(12):e951-e962. PubMed ID: 38056966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data on empirical estimation of the relationship between agency costs and ownership structure in Italian listed companies (2002-2013).
    Rossi F; Barth JR; Cebula RJ
    Data Brief; 2018 Jun; 18():2010-2012. PubMed ID: 29904708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are the shareholding and trading behaviors of diverse investors affected by the relaxation of day trading?
    Cheng WH; Ni Y; Ho TH; Chiang CJ; Huang P; Cheng Y
    PLoS One; 2021; 16(4):e0250121. PubMed ID: 33891620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does foreign ownership affect corporate sustainability disclosure in Pakistan? A sequential mixed methods approach.
    Rustam A; Wang Y; Zameer H
    Environ Sci Pollut Res Int; 2019 Oct; 26(30):31178-31197. PubMed ID: 31463751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. China's Insurance Regulatory Reform, Corporate Governance Behavior and Insurers' Governance Effectiveness.
    Li H; Zhang H; Tsai SB; Qiu A
    Int J Environ Res Public Health; 2017 Oct; 14(10):. PubMed ID: 29039781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Water Matter? The Impact of Water Vulnerability on Corporate Financial Performance.
    Zheng L; Ye L; Wang M; Wang Y; Zhou H
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.